Lactate Is a Crucial Energy Source For Multiple Myeloma (MM) Cells In Bone Marrow MicroenvironmentIntroduction It has been reported that the growth of certain cancer cells depends on the Warburg effect (aerobic
. . . . 1525 Abstract Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow lead- ing to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable ...
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97. Article CAS PubMed Google Scholar Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-...
The role of auto-SCT in the treatment of multiple myeloma (MM) in the era of novel agents continues to evolve. It is now clear that the depth of response and clinical outcomes have significantly improved as a result of the combination of these strategies
The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we dete
I taught university level courses in sociology and criminal justice for over 30 years but now I'm retired and at 72 was diagnosed with multiple myeloma, bone marrow cancer. This site is now a chronicle of my journey with myeloma.
MM indicates multiple myeloma; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; n.a., not available; and HDAC, histone deacetylase. * Clinical response is the response rate (defined as greater than 50% reduction in tumor burden) for the drug as a single agent in MM. Note that for PLD there...
Bone marrow (BM) angiogenesis significantly influences disease progression in multiple myeloma (MM) patients and correlates with adverse prognosis. The present study shows a statistically significant correlation of the AP-1 family member JunB with VEGF,
The present disclosure provides methods for treating multiple myeloma that comprise administering isatuximab to the individual at a dose of 10 mg/kg on Days 1, 8, 15, and 22 of a fi
Osteolytic bone disease is a frequent and severe complication of multiple myeloma (MM). MM cells interact with stromal cells in the bone marrow niche to create an environment that is favorable for tumor growth, in particular by inducing differentiation and activity of bone-resorbing osteoclasts, ...